A. Journal Articles


Bryant J.  What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent data monitoring committee in the U.S. Cancer Cooperative Group setting?  *Statist Med* 2004;23:1507-1511.


Cairns JA, Hallstrom A, Held P.  Should all trials have a data safety and monitoring committee?  *Am Heart J* 2001;141:156-163.


Califf RM, Ellenberg SS.  Statistical approaches and policies for the operations of data and safety monitoring committees.  *Am Heart J* 2001;141:301-303.


Canner PL.  Monitoring clinical trial data for evidence of adverse or beneficial treatment effects.  *INSEIR* 1977;76:131-149.


Chen YHJ, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising. *Statist Med* 2004;23:1023-1038.

Chen YHJ, DeMets DL, Lan KKG. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. *Controlled Clin Trials* 2003;24:16-27.


DeMets DL, Gail MH. Use of logrank tests and group sequential methods at fixed calendar times. *Biometrics* 1985;41:1039-1044.


DeMets DL, Ware JH. Asymmetric group sequential boundaries for monitoring clinical trials. *Biometrika* 1982;69:661-663.


Grant A. Stopping clinical trials early. Data monitoring committees may have important role. *BMJ* 2004;329:525-526.


Phillips DF. IRBs search for answers and support during a time of institutional change. *JAMA* 2999;283:729-780.


Bibliography: Monitoring Treatment Effectiveness and Safety in Clinical Trials


Pocock SJ. When (not) to stop a clinical trial for benefit. *JAMA* 2005;294:2228-2230.


**B. Special Issues of Journals**
Controlled Clinical Trials 2003;24(1):4-106.


C. Books and Book Chapters


D. Regulatory Guidelines and Other Guidance Document (MORE TO ADD!)


[NIMH] NIMH policy on data and safety monitoring in clinical trials (September 2002).  

[NINDS] NINDS guidelines for data and safety monitoring in clinical trials. 